Identity
ACE-031 is an investigational soluble activin-receptor fusion protein that binds myostatin and related ligands.
Selected study only; not a complete clinical review.
Peptide library
ACE-031
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
The healthy-women study measured lean mass after a single dose, not sustained strength or function. The later Duchenne trial was stopped with vascular safety concerns. Body-composition changes alone are an inadequate benefit–risk argument.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
48 healthy postmenopausal women; single-dose study.
What the sources found
Lean mass and thigh muscle volume increased at the highest studied dose; this does not establish improved strength.
Regulatory scope
Current authorization for the exact product and jurisdiction was not independently checked in this snapshot. A clinical trial is not marketing authorization.
What remains unknown
Selected indexed primary-study abstract reviewed. Full methods, bias, all safety outcomes, product stability, current jurisdictional authorization and a comprehensive literature search remain outstanding. This is not a complete clinical review.
How it works
ACE-031 is an investigational soluble activin-receptor fusion protein that binds myostatin and related ligands.
The study-specific findings below distinguish biological activity from demonstrated treatment benefit.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Reported adverse effects
- Injection-site redness was reported. Repeat-dose safety needs separate assessment.
- A later Duchenne muscular dystrophy study stopped over nosebleeds and telangiectasias; short-term single-dose tolerability does not resolve that concern.
Selected study only; not a complete clinical review.
Source · Abstract: methods and results
Repeated-dose study in boys with Duchenne muscular dystrophy.
Contraindications
- A complete contraindication and interaction review remains outstanding.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Sources used for this snapshot
Claim-by-claim evidence
Benefits
Lean mass and thigh muscle volume increased at the highest studied dose; this does not establish improved strength.
Selected study only; not a complete clinical review.
Adverseeffects
Injection-site redness was reported. Repeat-dose safety needs separate assessment.
Selected study only; not a complete clinical review.
Adverseeffects
A later Duchenne muscular dystrophy study stopped over nosebleeds and telangiectasias; short-term single-dose tolerability does not resolve that concern.
Repeated-dose study in boys with Duchenne muscular dystrophy.
References
A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. 2013.
PMID: 23169607
Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. 2017.
PMID: 27462804
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.